Owp Patent-Cliff Exposure & CMS Drug Spending Portfolio

Owp (US): 4 reconciled FDA prescription therapies, $353K 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2040-01-01
2024 CMS Total Public Spend$353K
2024 Medicare Part D Spend$88K
2024 Medicaid Spend$265K
California HCAI SB 17 Filings3 WAC filings (max 19.1% 2-yr change)